Evidence map›Paper›PMID 35227226›Full record

ArticleBMC cancer2022

Compliance with recommended cancer patient pathway timeframes and choice of treatment differed by cancer type and place of residence among cancer patients in Norway in 2015-2016.

Yngvar Nilssen, Odd Terje Brustugun, Morten Tandberg Eriksen, Marianne G Guren, Erik Skaaheim Haug, Bjørn Naume, Ellen Schlichting, Bjørn Møller

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yngvar NilssenDepartment of Registration, Cancer Registry of Norway, Oslo, Norway. ynni@kreftregisteret.no.
Odd Terje BrustugunDepartment of Oncology, Drammen Hospital, Vestre Viken Hospital Trust, Drammen, Norway.
Morten Tandberg EriksenInstitute of Clinical Medicine, University of Oslo, Oslo, Norway.
Marianne G GurenInstitute of Clinical Medicine, University of Oslo, Oslo, Norway.
Erik Skaaheim HaugSection of Urology, Vestfold Hospital Trust, Tønsberg, Norway.
Bjørn NaumeInstitute of Clinical Medicine, University of Oslo, Oslo, Norway.
Ellen SchlichtingDepartment of Breast and Endocrine Surgery, Department of Cancer, Oslo University Hospital, Oslo, Norway.
Bjørn MøllerDepartment of Registration, Cancer Registry of Norway, Oslo, Norway.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCancer patient pathways (CPPs) were implemented in Norway to reduce unnecessary waiting times, regional variations, and to increase the predictability of cancer care for the patients. This study aimed to determine if 70% of cancer patients started treatment within the recommended time frames, and to identify potential delays.

methodsPatients registered with a colorectal, lung, breast, or prostate cancer diagnosis at the Cancer Registry of Norway in 2015-2016 were linked with the Norwegian Patient Registry and Statistics Norway. Adjusting for sociodemographic variables, multivariable quantile (median) regressions were used to examine the association between place of residence and median time to start of examination, treatment decision, and start of treatment.

resultsThe study included 20 668 patients. The proportions of patients who went through the CPP within the recommended time frames were highest among colon (84%) and breast (76%) cancer patients who underwent surgery and lung cancer patients who started systemic anticancer treatment (76%), and lowest for prostate cancer patients who underwent surgery (43%). The time from treatment decision to start of treatment was the main source of delay for all cancers. Travelling outside the resident health trust prolonged waiting time and was associated with a reduced odds of receiving surgery and radiotherapy for lung and rectal cancer patients, respectively.

conclusionsAchievement of national recommendations of the CCP times differed by cancer type and treatment. Identified bottlenecks in the pathway should be targeted to decrease waiting times. Further, CPP guidelines should be re-examined to determine their ongoing relevance.

Indexed as

AdultAgedAged, 80 and overCritical PathwaysFemaleGeographyHumansInformation Storage and RetrievalMaleMiddle AgedNeoplasmsNorwayPatient Acceptance of Health CarePatient ComplianceRegistriesTime FactorsBreast cancerCancer patient pathwaysColorectal cancerLung cancerProstate cancerWaiting time

Identifiers

PMID35227226
PMCPMC8883731

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.